gastrin 17 (G 17)

Subscribe to Selected New Research on gastrin 17

110 relevant articles (4 outcomes, 13 trials/studies) found for this Bio-Agent

Also Known As:

G 17; SHG17NS; gastrin heptadecapeptide; gastrin-17; heptadecapeptide gastrin; little gastrin I; 18-34-Gastrin, 18-(5-oxo-L-proline)-

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Sipponen, P: 2 articles (06/2007 - 07/2002)
2.	Sipponen, Pentti: 2 articles (10/2005 - 05/2005)
3.	Amirzargar, Aliakbar: 1 article (02/2008)
4.	Rafiee, Reza: 1 article (02/2008)
5.	Khosravi, Farideh: 1 article (02/2008)
6.	Shahidi, S Mehdi: 1 article (02/2008)
7.	Rakhshani, Naser: 1 article (02/2008)
8.	Nikbin, Behrouz: 1 article (02/2008)
9.	Haj-Sheykholeslami, Arghavan: 1 article (02/2008)
10.	Massarrat, Sadegh: 1 article (02/2008)

Related Diseases

1.	Atrophic Gastritis 02/01/2007 - "The PGI, PGR and G-17 values were related significantly with the grades and/or sites of atrophic gastritis (P<0.01)" 01/01/2007 - "None of the markers of pepsinogen (PG) I, PGII, and gastrin 17 (G17) indicated atrophic gastritis" 10/01/2004 - "CONCLUSION: The test panel composed of pepsinogen I and protein stimulated gastrin-17 may be used as the "serological gastric biopsy" detecting multifocal atrophic gastritis" 07/01/2002 - "We investigated whether atrophic gastritis can be diagnosed and typed non-endoscopically if the serum levels of pepsinogen I (S-PGI) and gastrin-17 (S-G-17) are assayed in connection with H" 07/01/2002 - "Serum levels of amidated gastrin-17 and pepsinogen I in atrophic gastritis: an observational case-control study." Order ALL the reference details at left...
2.	Neoplasms (Cancer) 08/01/2007 - "Moreover, tumor perfusion measurements corroborated the MR results, indicating a significant reduction in tissue perfusion after VTA treatment (mean tissue fluorescence, 570.4 arbitrary units [au] per gram +/- 27 vs 161.7 au/g +/- 17; P < .05)" 03/01/2008 - "Gastrin-17 dose dependently increased c-fos induction in both cancer cell lines" 04/07/2006 - "CONCLUSION: The P64K-polypeptide cross-linked immunogen immunized rabbit and achieved a higher titer antibody against gastrin 17 than the G17P64K fusion protein immunogen, which could inhibit the growth of the tumor cell SW480." 07/01/1995 - "Tumor weight evaluation represented a good parameter of neoplasm evolution: of 19 cases weighing less than 250 g, 17 had no evidence of disease after surgery, and 2 had an unfavorable prognosis" 11/01/1986 - "These data demonstrate that physiological concentrations of gastrin-17 can stimulate the growth of a human cancer cell line and that some degree of synchronization may be necessary to demonstrate similar effects in other cell lines" Order ALL the reference details at left...
3.	Birth Weight (Birth Weights) 10/18/2003 - "Random effects models showed a negative association between grandmothers' smoking and birth weight of grandchildren (beta regression coefficient -24 g, -50 g to 3 g), but this effect was eliminated after adjustment for maternal smoking (0 g, -26 g to 26 g).No association was evident among the offspring of non-smoking mothers (n = 6105; 14 g, -17 g to 46 g), and after adjustment for maternal birth weight, adult height and body mass index, grandmothers' smoking was positively associated with the birth weight of grandchildren (45 g, 10 g to 80 g)" 11/15/2001 - "Birth weights were stratified into 500-g increments beginning with <or=999 g; 17% of the population had some school-identified disability" 09/01/1989 - "For infants born between 1975-1985, 26% of surviving infants with birth weights below 800 g, 17% of survivors with birth weights between 750-1000 g, and 11% of survivors with birth weights between 1000-1500 g have major handicaps at 1 or 2 years of age" 11/01/1987 - "50 women with a mean age of 22 years have been divided into three groups (13 women had a birth weight below 1.500 g, 17 women were within the range of 1.500 g and 2.000 g and 20 women between 2.001 and 2.500 g)" Order ALL the reference details at left...
4.	Duodenal Ulcer (Curling's Ulcer) 02/01/1984 - "A dose response study of the effect on gastric acid secretion of synthetic human gastrin-17 in doses of 50,200, and 500 ng/kg/h was performed in eight healthy volunteers and in eight patients with duodenal ulcer" 07/31/1987 - "NH2-terminal of gastrin-17 in duodenal ulcer disease: identification of progastrin-17." 09/01/1986 - "Comparison of acid secretory responsiveness to gastrin heptadecapeptide and of gastrin heptadecapeptide pharmacokinetics in duodenal ulcer patients and normal subjects." 01/01/1985 - "The ratio G-17/G-34 was similar in placebo-treated normal subjects and placebo-treated patients with gastric or duodenal ulcers" 01/01/1984 - "In contrast to healthy subjects, duodenal ulcer patients in the active phase contain large amounts of a peptide in serum and antrum which react with antiserum specific for the N-terminus, but not the C-terminus of gastrin-17" Order ALL the reference details at left...
5.	Gastritis 02/01/2008 - "The sensitivity and specificity of the PG I:II ratio (< or =3) and gastrin 17 (>17 pmol/mL) together were 9.4% and 99% for screening corpus-predominant gastritis and 14.8% and 97.8%, respectively, for screening intestinal metaplasia in the corpus" 07/01/1983 - "The results suggest that gastrin cells process gastrin-17 abnormally during the acute phase of duodenal ulcer and gastritis." 07/01/1983 - "Increased concentrations of the NH2-terminal fragment of gastrin-17 in acute duodenal ulcer and acute gastritis." 02/01/2008 - "With the extension of gastritis, PGII was increased up to 2.5 times (6.6 +/- 2.8 microg/mL in normal mucosa, 9.5 +/- 6.7 microg/mL in antral gastritis, and 16.9 +/- 12.4 microg/mL in corpus-predominant gastritis; P < .01), PGI increased slightly (88.3 +/- 29.4 microg/mL in normal mucosa and 111.2 +/- 71.4 microg/mL in corpus-predominant gastritis), and gastrin 17 was increased substantially in corpus-predominant gastritis (15.3 +/- 19.5 pmol/mL vs 3.8 +/- 5.7 pmol/mL in normal mucosa)" 02/01/2007 - "Patients with atrophic corpus gastritis had low PGI and PGR values and high G-17 level, and patients with atrophic antral gastritis had low G-17 level" Order ALL the reference details at left...

Related Drugs and Biologics

1.	Antibodies
2.	Pepsinogen A (Pepsinogen)
3.	Pepsinogens
4.	Gastrins
5.	Antral
6.	big gastrin (G34)
7.	Glycine (Aminoacetic Acid)
8.	Cholecystokinin B Receptor
9.	Pepsinogen C
10.	Biological Markers (Surrogate Marker)

Related Therapies and Procedures

1.	Proximal Gastric Vagotomy
2.	Vagotomy
3.	Transplants (Transplant)
4.	Drug Therapy (Chemotherapy)

Best Treatments:
Research Summary Report
on Atrophic Gastritis

*WARNING* This specific disease subtype has a relatively small number of significant evidence outcomes. You may proceed to order anyway, or go back to the search field and enter a more general type of the target illness. Once your report has been ordered, however, we can't refund the purchase.

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 15 Outcomes
Top 200 Key Drugs and Biologics
Top 23 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year